In 1050 patients with HR-positive, ERBB2-negative advanced breast cancer, first-line vs second-line CDK4/6 inhibitors did not improve OS, a key secondary end point (median 47.9 vs 48.1 months; HR 0.91, P=.24), and caused more grade ≥3 events.
RCTn = 1,050
Wortelboer et al. Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial